Sara Hestehave

New preclinical evidence strengthens the link between CGRP and migraine-associated photophobia.

CGRP induced light avoidance and headache-like pain in rats, closely mirroring human migraine provocation studies, offering strong translational relevance for studying migraine.

doi.org/10.1186/s101...

It's finally out🥳
My main piece from my postdoc-project at UCL is now out in PNAS💪🏼This project was a dream come true, and I'm eternally grateful for my brilliant supervisor, Sandrine Geranton, and the funder, @arthritisuk.bsky.social, for making it possible!

www.pnas.org/doi/10.1073/...

Beautiful work by Jenny and @okalliokoski.bsky.social 💪🏼 But I'm depressed by the theme, and how fraudulent studies undermine our scientific foundation 🙄

If anyone needs an insightful talk for a meeting or graduate school, then Otto gives an excellent overview of the topic !!

Today it's my turn at #EFIC2025 !! Come visit my poster (A1.W.05) and join the guided posterwalk at 12.45 😃

Excited to be at #EFIC2025 in Lyon these days!

I've brought along two of our students, who are presenting their results on our newly established "climbing assay" for objective assessment of pain in mice. So, please stop by poster C.19 to have a chat with Morten and Tobias 😃
#pain #research

Our @painthejournal.bsky.social paper “Small molecule targeting NaV1.7 via inhibition of CRMP2-Ubc9 interaction reduces pain-related outcomes in a rodent osteoarthritic model” was featured in the April 2025 Science, Medicine, & the Anesthesiologist (SM&A) column of Anesthesiology.

A compound with potential for managing diverse pain conditions!

@khannalabuf.bsky.social @shestehave.bsky.social & team identify C2230 that targets Ca2+ channels & relieves neuropathic, orofacial, and osteoarthritis pain in models: https://www.jci.org/articles/view/177429

Another exciting preprint coming out from the Géranton-lab 😍 👏🏼 Well done everyone 💪🏼
#uclresearch #stress #pain #epigenetics

Small molecule targeting NaV1.7 via inhibition of... : PAIN by inhibition of the voltage-gated sodium channel NaV1.7. We previously identified compound 194 as an indirect inhibitor of NaV1.7 by preventing SUMOylation of the NaV1.7-trafficking protein, collapsi...

Now in #PAIN: “Small molecule targeting NaV1.7 via inhibition of CRMP2-Ubc9 interaction reduces pain-related outcomes in a rodent osteoarthritic model” by @khannalabuf.bsky.social
et al. bit.ly/3OQCjsY

Uncoupling the CRMP2-CaV2.2 Interaction Reduces Pain-Like Behavior in a Preclinical Joint-Pain Model Osteoarthritis (OA) represents a significant pain challenge globally, as current treatments are limited and come with substantial and adverse side effects. Voltage-gated calcium channels have proved to be pharmacologically effective targets, with multiple Food and Drug Administration-approved CaV2.2 modulators available for the treatment of pain. Although effective, drugs targeting CaV2.2 are complicated by the same obstacles facing other pain therapeutics—invasive routes of administration, narrow therapeutic windows, side effects, and addiction potential.

Now out in press!!

Uncoupling the CRMP2-CaV2.2 Interaction Reduces Pain-Like Behavior in a Preclinical Joint-Pain Model - The Journal of Pain www.jpain.org/article/S152...

📣Latest from our lab: a collaboration with labs from Hunan Normal University (Tang), NYU (Arora), Rutgers (Korczeniewska) & UTDallas (Price)
JCI - C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models www.jci.org/articles/vie...

A significant problem, that we also encountered when performing a meta analysis, and that @okalliokoski.bsky.social has since been pushing to show the word. I'm excited to see his involvement in this news-story, and hope that the scientific community can find ways to combat it in the future !

Cheering for Jesse, as he defends his thesis today !!

#phd #nakedmolerats #pain #UniversityOfCopenhagen

Great work, Tomás !